Drug targeting

Details Drug targeting Drug targeting

2005-04-19

2005-04-19

Travers, Russell (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S396000, C514S385000, C514S398000, C514S655000, C514S650000, C514S654000, C514S659000

Reexamination Certificate

active

06881748

ABSTRACT:
A bioreductive conjugate comprises a bioreductive moiety with at least one therapeutic agent linked thereto and physiologically acceptable derivatives thereof. The bioreductive moiety incorporates an aromatic ring substituted with a nitro group and the conjugate is such that bioreduction of the nitro group causes release of the therapeutic agent by a through bond elimination and the residue of the bioreductive moiety to undergo an intramolecular cyclization reaction in which the nitrogen of the original nitro group provides an atom of the thus formed ring.

REFERENCES:
patent: 4261883 (1981-04-01), Smolarsky
patent: 5652255 (1997-07-01), Adams et al.
Lipman, Curr Rheumatol Rep, Dec. 2001:3(6) 513-9.*
Hay et al, “Nitroimidazole-based ‘extruded mustards’ designed as reductively activated hypoxia-selective cytotoxins”, Chemical Abstracts 125:211954.
Palmer et al, “Reductive Chemistry of the Novel Hypoxia-Selective Cytotoxin 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide”, Chemical Abstracts 122:230131 (1995).
Atwell et al, “Relationship between structure and kinetics of cyclization of 2-aminoaryl amides: potential prodrugs of cyclization-activated aromatic mustards”, Chemical Abstracts 120:216381.
Jenkins et al, “Synthesis and evaluation of α-[(2-haloethyl)=amino)methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of α-[(1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol (ESU-1069) and its analogs which are radiosensitizers and bioreductively activated cytoxins”, Chemical Abstracts 113:171945 (1990).
Siim et al “Nitro reduction as an electronic switch for bioreductive drug activation”, Chemical Abstracts 128:238843 (1998).
Hay et al, “Nitroimidazole-based “extruded mustards” designed as reductively activated hypoxia-selective cytotoxins”, Anti-Cancer Drug Design 11(5):383-402 (1996).
Rauth et al, “Bioreductive therapies: An overview of drugs and their mechanisms of action”, International Journal of Radiation 42(4):755-762 (1998).
Nudelman et al “Hypoxic radiosensitizers: substituted styryl derivatives”, Arch. Pharm. 327(10):619-625 (1994).
Jaffar et al, “Bioreductive drugs: Selectivity towards hypoxic tissue”, Expert Opinion on Therapeutic Patents 9(10):137 1380 (1999).

Affiliated with

Also associated with

Rating

Drug targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Drug targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug targeting will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3411145